Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alto Neuroscience, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

33 comunicati stampa

Guarda tutti i comunicati
14/01/2026
Psichiatria
Salute
Sanità
Farmaceutica
Biotecnologia
Industria
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
13/01/2026
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Eventi
Industria
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
03/12/2025
Mercato azionario
Finanza
Psichiatria
Salute
Scienza
Farmaceutica
Biotecnologia
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Eventi
Fiere
Mercato azionario
Analisi di mercato
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Psichiatria
Scienza
Medicina - Varie
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
28/10/2025
Eventi
Web e Social Network
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alto Neuroscience to Participate in Upcoming Investor Conferences
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Scienza
Associazioni/Professionisti
Farmaceutica
Psichiatria
Medicina - Varie
Biotecnologia
Finanza
Igiene alimentare
Salute
Alto Neuroscience Announces $50 Million Private Placement Financing
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
03/10/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Industria
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
09/09/2025
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0
18/08/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Eventi
Alto Neuroscience to Participate in Upcoming Investor Conferences
Fonte
Alto Neuroscience, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0